Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis
Hepatology · 2023-07 · 78 (1) · 88-102
DOI: 10.1097/hep.0000000000000047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology, online erschienen am 03.01.2023. Verfasst von Yibin Che und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Butyrates, Carcinoma, Hepatocellular, Gastrointestinal Microbiome, Liver Neoplasms. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Gut microbiota are recognized to be important for anticancer therapy, yet the underlying mechanism is not clear. Here, through the analysis of clinical samples, we identify the mechanism by which the gut microbial metabolite butyrate inhibits HCC and then explore new strategies for HCC treatment. Approach and Results: In our study, we demonstrate that gut microbial metabolite butyrate improves anticancer therapy efficacy by regulating intracellular calcium homeostasis. Using liquid chromatography-mass spectrometry analysis, we found that butyrate metabolism is activated in HCC patients compared with healthy individuals. Butyrate levels are lower in the plasma of HCC patients by gas chromatography-mass spectrometry (GC-MS) analysis. Butyrate supplementation or depletion of short-chain Acyl-CoA dehydrogenase (SCAD) gene (ACADS), encoding a key enzyme for butyrate metabolism, significantly inhibits HCC proliferation and metastasis. The profiling analysis of genes upregulated by butyrate supplementation or ACADS knockdown reveals that calcium signaling pathway is activated, leading to dysregulation of intracellular calcium homeostasis and production of reactive oxygen species. Butyrate supplementation improves the therapy efficacy of a tyrosine kinase inhibitor sorafenib. On the basis of these findings, we developed butyrate and sorafenib coencapsulated mPEG-PLGA-PLL nanoparticles coated with anti-GPC3 antibody (BS@PEAL-GPC3) to prolong the retention time of drugs and enhance drug targeting, leading to high anticancer efficacy. BS@PEAL-GPC3 nanoparticles significantly reduce HCC progression. In addition, BS@PEAL-GPC3 nanoparticles display excellent HCC targeting with excellent safety. Conclusions: In conclusion, our findings provide new insight into the mechanism by which the gut microbial metabolites inhibit HCC progression, suggesting a translatable therapeutics approach to enhance the clinical targeted therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai, China.
- Shanghai Institute of Transplantation, Shanghai, China.
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Cancer Institute, Shanghai, China.
- State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, School of Biomedical Engineering, Shanghai, China.
- Shanghai Cancer Institute, Renji Hospital, Shanghai, China.
ORCID-Profile: Yibin Che, Guoyu Chen, Yourong Duan, Haizhong Feng, Qiang Xia
Zitieren
APA
Che, Y., Chen, G., Guo, Q., Duan, Y., Feng, H., & Xia, Q. (2023). Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis. Hepatology, 78(1), 88-102. https://doi.org/10.1097/hep.0000000000000047
Vancouver
Che Y, Chen G, Guo Q, Duan Y, Feng H, Xia Q. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis. Hepatology. 2023;78(1):88-102. doi:10.1097/hep.0000000000000047
BibTeX
@article{Che2023,
author = {Che, Yibin and Chen, Guoyu and Guo, Qianqian and Duan, Yourong and Feng, Haizhong and Xia, Qiang},
title = {Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis},
journal = {Hepatology},
year = {2023},
volume = {78},
number = {1},
pages = {88--102},
doi = {10.1097/hep.0000000000000047}
}
EUVIMED